Can you elaborate? In particular, this:
>>>>Five-year data indicate a significant progression-free survival benefit, with 60% of patients free of progression.
So far im with you.
>>>>Even after 60.2 months of follow-up, the median progression-free survival has not yet been reached [1]
This sounds awful? Or contradictory at best?